[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550540":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":54,"centralContacts":59,"locations":64,"responsibleParty":79,"collaborators":10,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":90,"minAge":91,"maxAge":10,"enrollmentInfo":92,"targetDuration":95,"studyType":96,"phases":10,"briefSummary":97,"conditions":98,"keywords":103,"overallStatus":67,"whyStopped":10,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"Norwegian University of Science and Technology","OTHER",[8,19,22],{"label":9,"type":10,"description":11,"interventionNames":12},"MCI",null,"Recruitment according to relevant clinical assessment and ICD-criterias.",[13,14,15,16,17,18],"Device: MRI Scanning","Device: 64-channel EEG","Device: Polysomnography","Biological: Blood samples","Biological: Fecal samples","Behavioral: Cognitive tests",{"label":20,"type":10,"description":11,"interventionNames":21},"Mild AD",[13,14,15,16,17,18],{"label":23,"type":10,"description":24,"interventionNames":25},"Control","Equivalent number of research participants as in the MCI and mild AD group.",[13,14,15,16,17,18],[27,32,36,40,45,49],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":10},"DEVICE","MRI Scanning","MRI scanning with volumetric, resting and activity-based sequences.",[23,9,20],{"type":28,"name":33,"description":34,"armGroupLabels":35,"otherNames":10},"64-channel EEG","EEG to quantifiy electric activity.",[23,9,20],{"type":28,"name":37,"description":38,"armGroupLabels":39,"otherNames":10},"Polysomnography","A randomized group will undergo polysomnography.",[23,9,20],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":10},"BIOLOGICAL","Blood samples","Analysis of specific blood biomarkers.",[23,9,20],{"type":41,"name":46,"description":47,"armGroupLabels":48,"otherNames":10},"Fecal samples","Analysis of bacterial composition.",[23,9,20],{"type":50,"name":51,"description":52,"armGroupLabels":53,"otherNames":10},"BEHAVIORAL","Cognitive tests","Interview-based cognitive tests for assesment of cognitive levels.",[23,9,20],[55],{"name":56,"affiliation":57,"role":58},"Axel Sandvig, Prof., MD, PhD","Norwegian University of Science and Technology (NTNU) & St. Olavs Hospital, Trondheim University Hospital","PRINCIPAL_INVESTIGATOR",[60],{"name":56,"role":61,"phone":62,"phoneExt":10,"email":63},"CONTACT","72 57 56 20","axel.sandvig@ntnu.no",[65],{"facility":66,"status":67,"city":68,"state":69,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":10},"Norwegian University of Sciene and Technology \u002F Norges teknisk-naturvitenskapelige universitet (NTNU)","RECRUITING","Trondheim","Trønderlag","7030","Norway","NO",{"type":74,"coordinates":75},"Point",[76,77],10.39506,63.43049,{"lat":77,"lon":76},{"type":80,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100550540","multimodal-assesment-of-alzheimer-patients-100550540",false,"NCT06448403","Multimodal Assesment of Alzheimer Patients","Multimodal Assessment of Cognitive Impairment in Alzheimer Patients","MultiAD","Inclusion Criteria:\n\n* MCI and AD according to relevant ICD-criterias.\n* Control cohort is age and gender matched with other cohorts.\n\nExclusion Criteria:\n\n* Uneligibility for any of the planned neuroimagery devices (MRI, EEG)\n* AD diagnosis before the age of 65 (Early-onset AD).\n* Brain tumor\n* Traumtic head injury\n* Earlier neurosurgery\n* Other neyrodegenerative diseases (i.e Parkinson and ALS)\n* Diseases related to inflammation and auto-immunity (i.e MS)",true,"ALL","65 Years",{"count":93,"type":94},60,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this study is to learn more about the changes in the brains of patients with cognitive impairment (MCI) and Alzheimer's Disease (AD).\n\nThe main questions the study aims to answer are:\n\n1. What findings can be used to earlier detect patients that will develop Alzheimers?\n2. Which differences are seen between healthy and cognitively impaired patients?\n3. Which differences are seen between patients with Alzheimers disease?\n\nParticipants will undergo:\n\n* Cognitive tests\n* Magnetic resonance imaging (MRI)\n* Electroencephalography (EEG)\n* Blood sample collection\n* Fecal sample collection\n* A randomized group will undergo polysomnography analysis.",[99,100,101,102],"Mild Cognitive Impairment","Alzheimer Disease, Late Onset","Cognitive Impairment","Dementia",[104,105,106,107,108,102,109],"Alzheimer Disease (AD)","Mild cognitive impairment (MCI)","Brain Diseases","Nervous System Disorders","Neurodegenerative Diseases","Cognitive impairment","2025-08-04",{"date":112,"type":113},"2025-08-07","ACTUAL",{"date":115,"type":113},"2024-07-01",{"date":117,"type":94},"2030-12-29",{"name":5,"class":6},1]